Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. KYV-101 is our proprietary CD19 chimeric antigen receptor (CAR) T-cell therapy for autoimmunity, in clinical trials and investigator-initiated trials across the US and Europe. During the year ended December 31, 2023, the Company reported a net loss of $60.4 million, compared to